Boasting a patent estate that the company's CEO said "covers everything that can be done" in antisense, Isis Pharmaceuticals Inc. entered a strategic alliance with Alnylam Pharmaceuticals Inc. that combines the pair's knowledge and expertise in the burgeoning field of RNAi. (BioWorld Today)
Industry pundits have been chanting about "consolidation" for years, using each new buyout as a way of proving their forecast - which, let's face it, is pretty much a fail-safe prediction.
Amgen Inc. gained FDA approval of cinacalcet as a treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in those with parathyroid carcinoma - and NPS Pharmaceuticals Inc. gained a $10 million milestone payment as part of their licensing deal. (BioWorld Today)
